Phase 1 Relapsed/Refractory B-cell Malignancies Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07309900
Recruiting
Phase 1
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.94 enrolled11 locationsNCT06590961
Recruiting
Phase 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc60 enrolled9 locationsNCT05780034
Recruiting
Phase 1
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University30 enrolled6 locationsNCT07002112